IDYA vs PCRX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 03, 2026

IDYA

61.4
AI Score
VS
IDYA Wins

PCRX

58.6
AI Score

Investment Advisor Scores

IDYA

61score
Recommendation
BUY

PCRX

59score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric IDYA PCRX Winner
Revenue 15.42M 369.77M PCRX
Net Income -210.99M 7.57M PCRX
Net Margin -1368.6% 2.0% PCRX
Operating Income -230.84M 11.17M PCRX
ROE -17.6% 1.1% PCRX
ROA -16.1% 0.6% PCRX
Total Assets 1.31B 1.24B IDYA
Cash 272.59M 205.88M IDYA
Current Ratio 10.45 5.04 IDYA
Free Cash Flow -165.21M 79.08M PCRX

Relative Price Performance (Last 90 Days)

IDYA 1M: -7.0% · 3M: -5.1% PCRX 1M: -5.2% · 3M: -1.5%

Current Technical Phase

IDYA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 45

RSI (14): 45.3 · Price: $37.36

PCRX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 51

RSI (14): 50.7 · Price: $25.21

Fundamentals Snapshot

Metric IDYA PCRX
Market Cap — —
Forward P/E -9.3 7.3
Trailing P/E — 71.5
Revenue (TTM) — —
Revenue Growth 0.6% 0.1%
Gross Margin -0.6% 0.8%
Operating Margin -13.8% 0.1%
EPS -1.89 0.35
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, IDYA is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.